Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naim Alkhouri

Showing results (91-100 of 306) with videos related to

Pageof 31
Sort By:
Hepatology Communications|June 19, 2025
Resmetirom-eligible population among US adults: An estimation analysis based on NHANES 2017-March 2020Phuc Le, Eda Kaya, Anh Phan, et al.
Cleveland Clinic Journal of Medicine|August 10, 2016
In Reply: Acute liver failureTavankit Singh, Nancy Gupta, Naim Alkhouri, et al.
ACG Case Reports Journal|July 10, 2015
Gastric Polyposis: A Rare Cause of Iron Deficiency Anemia in a Patient With Portal HypertensionSajan Jiv Singh Nagpal, Carole Macaron, Rish K Pai, et al.
Alcohol (Fayetteville, N.Y.)|March 9, 2024
The trends and incidence of alcohol-associated hepatitis hospitalizations from 2016-2020 and the impact of the COVID-19 pandemicMegan B Ghai, Pooja Rangan, Naim Alkhouri, et al.
Expert Opinion on Investigational Drugs|January 18, 2020
Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?Michael Ritchie, Ibrahim A Hanouneh, Mazen Noureddin, et al.
Journal of Clinical Gastroenterology|August 9, 2017
The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic PatientsAmandeep Singh, Phuc Le, Maajid M Peerzada, et al.
Expert Opinion on Investigational Drugs|September 15, 2019
GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)Naim Alkhouri, Eric Lawitz, Mazen Noureddin, et al.
Expert Opinion on Investigational Drugs|December 13, 2019
Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver diseasePhuc Le, Alexander Chaitoff, Michael B Rothberg, et al.
Biomarkers in Medicine|March 9, 2018
The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver diseaseChetan Mandelia, Mohammad Nasser Kabbany, Praveen Kumar Conjeevaram Selvakumar, et al.
Pediatric Clinics of North America|May 16, 2017
Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic ComplicationsPraveen Kumar Conjeevaram Selvakumar, Mohammad Nasser Kabbany, Valerio Nobili, et al.
Pageof 31

Showing results (91-100 of 306) with videos related to

Sort By:
Pageof 31
Hepatology Communications|June 19, 2025
Resmetirom-eligible population among US adults: An estimation analysis based on NHANES 2017-March 2020Phuc Le, Eda Kaya, Anh Phan, et al.
Cleveland Clinic Journal of Medicine|August 10, 2016
In Reply: Acute liver failureTavankit Singh, Nancy Gupta, Naim Alkhouri, et al.
ACG Case Reports Journal|July 10, 2015
Gastric Polyposis: A Rare Cause of Iron Deficiency Anemia in a Patient With Portal HypertensionSajan Jiv Singh Nagpal, Carole Macaron, Rish K Pai, et al.
Alcohol (Fayetteville, N.Y.)|March 9, 2024
The trends and incidence of alcohol-associated hepatitis hospitalizations from 2016-2020 and the impact of the COVID-19 pandemicMegan B Ghai, Pooja Rangan, Naim Alkhouri, et al.
Expert Opinion on Investigational Drugs|January 18, 2020
Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?Michael Ritchie, Ibrahim A Hanouneh, Mazen Noureddin, et al.
Journal of Clinical Gastroenterology|August 9, 2017
The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic PatientsAmandeep Singh, Phuc Le, Maajid M Peerzada, et al.
Expert Opinion on Investigational Drugs|September 15, 2019
GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)Naim Alkhouri, Eric Lawitz, Mazen Noureddin, et al.
Expert Opinion on Investigational Drugs|December 13, 2019
Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver diseasePhuc Le, Alexander Chaitoff, Michael B Rothberg, et al.
Biomarkers in Medicine|March 9, 2018
The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver diseaseChetan Mandelia, Mohammad Nasser Kabbany, Praveen Kumar Conjeevaram Selvakumar, et al.
Pediatric Clinics of North America|May 16, 2017
Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic ComplicationsPraveen Kumar Conjeevaram Selvakumar, Mohammad Nasser Kabbany, Valerio Nobili, et al.
Pageof 31